Physician

Adam M Sun, MD

According to 2025 Medicare claims, Adam Sun, MD (NPI: 1497712715) practices nephrology in the Los Angeles-Long Beach-Glendale, CA market, with the plurality of this provider's patient population coming from Los Angeles, CA. Sun uses personal NPI as billing NPI and primary practice location at 91770-2326. Sun is affiliated with the APA ACO Inc. (ACO ID: D0215), participating under the REACH model.

Sun's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 248 traditional Medicare patients, billed 968 HCPCS/CPT codes, and received $185,707 in Medicare payments. The top billing code was 90960 (Dialysis services, 4 or more physician visits per month (20 years or older)). Part D data shows 3,524 prescription claims across 299 beneficiaries totaling $1,249,835 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 251 claims. Open Payments data shows 23 records totaling $772. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has declined steadily, from $381,416 to $185,707. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $717,924 and ending at $1,249,835. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $540 and ending at $1,080.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	473	3,032	$381,416
2016	467	2,622	$357,900
2017	420	2,240	$333,965
2018	370	1,854	$305,059
2019	348	1,528	$269,342
2020	289	1,312	$246,484
2021	233	967	$238,209
2022	263	1,076	$228,688
2023	253	1,015	$210,735
2024	248	968	$185,707

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	271	3,137	$717,924
2016	279	3,578	$1,286,172
2017	315	3,636	$1,520,025
2018	354	4,284	$1,811,964
2019	347	3,817	$1,643,963
2020	335	3,934	$2,412,057
2021	306	3,323	$836,878
2022	302	3,768	$1,293,211
2023	295	3,778	$1,416,793
2024	299	3,524	$1,249,835

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	204	$12,628
2016	N/R	194	$8,362
2017	N/R	169	$7,279
2018	N/R	108	$8,408
2019	N/R	60	$1,232
2020	N/R	165	$6,081
2021	N/R	255	$23,103
2022	N/R	189	$19,590
2023	N/R	295	$32,775
2024	N/R	251	$25,297

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
90960	Dialysis services, 4 or more physician visits per month (20 years or older)	46	390	$294
90961	Dialysis services, 2-3 physician visits per month (20 years or older)	22	44	$243
99204	New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more	33	33	$143
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	176	303	$107
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	110	146	$78

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	419	15,660	$283,132
Kerendia	Finerenone	306	11,317	$235,605
Rayaldee	Calcifediol	88	2,640	$123,388
Velphoro	Sucroferric Oxyhydroxide	62	1,860	$110,468
Dapagliflozin	Dapagliflozin Propanediol	167	5,280	$86,328

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7503	Tacrolimus, extended release, (envarsus xr), oral, 0.25 mg	N	N/R	20	$21,820
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	68	$1,204
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	43	$891
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	55	$840
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	37	$521

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	23	$772	AstraZeneca Pharmaceuticals LP
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

Nephrology providers in the Los Angeles-Long Beach-Glendale, CA market
Providers within practice ZIP code 91770-2326
Providers whose plurality patient county is Los Angeles, CA
Providers in California affiliated with APA ACO Inc. (REACH)

FAQ

What Medicare data is available for Adam M. Sun, MD?

Tedicare shows public-source Medicare data for Adam M. Sun, MD (NPI 1497712715), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Adam M. Sun, MD have ACO affiliation data?

Adam M. Sun, MD is shown with ACO affiliation data for APA ACO Inc. (REACH, ACO ID D0215).

What billing organization is linked to Adam M. Sun, MD?

A separate primary affiliated billing organization is not shown for this profile in the available data.

Does Adam M. Sun, MD have Open Payments data?

Adam M. Sun, MD has 23 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.